
    
      Following completion of at least 1 week of study drug for all subjects in group 1, the
      Sponsor will review the safety information of these subjects prior to enrolling off-treatment
      subjects into the next dose group. Dose escalation will continue in this manner (unless
      stopping criteria are met) until all groups have completed the study.
    
  